Incentivizing Antibiotic Development: Why Isn’t the Generating Antibiotic Incentives Now (GAIN) Act Working?

Antimicrobial resistance is of increasing global concern. To incentivize the creation of new treatments, the US Congress enacted the Generating Antibiotic Incentives Now Act (GAIN Act) of 2012, which provides benefits to manufacturers of Qualified Infectious Disease Products (QIDPs) including 5 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Darrow, Jonathan J, Kesselheim, Aaron S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986775/
https://www.ncbi.nlm.nih.gov/pubmed/32016125
http://dx.doi.org/10.1093/ofid/ofaa001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986775/
https://www.ncbi.nlm.nih.gov/pubmed/32016125
http://dx.doi.org/10.1093/ofid/ofaa001

Ejemplares similares